» Articles » PMID: 28784865

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Abstract

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.

Citing Articles

Single-Cell Sequencing and Transcriptome Analysis Explored Changes in Midnolin-Related Immune Microenvironment and Constructed Combined Prognostic Model for Pancreatic Cancer.

Guan X, Xu L, Liu J, Fei H, Wang C J Inflamm Res. 2025; 18:2975-2990.

PMID: 40026303 PMC: 11872096. DOI: 10.2147/JIR.S503326.


Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Adenocarcinoma: A Scoping Review with Meta-Analysis.

Tieranu C, Balaban D, Tabacelia D, Klimko A, Gheorghe C, Pereira S Diagnostics (Basel). 2025; 15(4).

PMID: 40002589 PMC: 11854302. DOI: 10.3390/diagnostics15040437.


Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and Meta-analysis of Latest Randomized Controlled Trials.

Chan A, Zhao Y, Tan H, Chua D, Ng K, Lee S Ann Surg Oncol. 2025; .

PMID: 39987384 DOI: 10.1245/s10434-024-16674-y.


Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol.

Stoop T, Seelen L, van t Land F, van der Hout A, Scheepens J, Ali M BMC Cancer. 2025; 25(1):299.

PMID: 39972248 PMC: 11841322. DOI: 10.1186/s12885-025-13554-w.


Impact of low muscle mass and myosteatosis on treatment toxicity and survival outcomes in non-resectable pancreatic cancer patients treated with chemoradiotherapy.

Perrier M, Fontaine M, Bertin E, Carlier C, Botsen D, Djelouah M Eur J Clin Nutr. 2025; .

PMID: 39910182 DOI: 10.1038/s41430-025-01566-5.